Evommune Inc. (EVMN)
NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EVMN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $291.10M
- EPS (TTM)
- -$3.83
- Dividend yield
- None
- 52-week range
- 4.94 – 33.20
- Day range
- 6.96 – 7.24
- Volume / Avg
- 549.40K / 841.65K
- Beta
- —
- Shares outstanding
- 41.35M
- Next earnings
- Dec 10, 2026
52-week range
EVMN stock today
Shares of Evommune (EVMN) finished lower on Nov 20 at $7.04, a drop of 2.76% or $0.20 per share, versus the S&P 500's 3.70% decline. At this level, EVMN sits near the bottom of its 52-week range of $4.94 to $33.20: 78.8% below the high, set on Feb 10, 2026 and 42.5% above the low. EVMN is down 58.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.4%.
Evommune has posted a net loss over the last twelve months (EPS of -$3.83), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 10; analysts expect EPS of -$0.82.
Summary generated from market data by MetaCap's automated system. Methodology
About Evommune
Company profileEvommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Luis C. Pena
- Headquarters
- Palo Alto, CA
- Employees
- 48
- IPO year
- 2025
- Website
- evommune.com
Financial highlights
Full financialsIn fiscal 2025, Evommune generated $13.0 million in revenue, up 85.7% from fiscal 2024. Evommune reported a net loss of $68.9 million, compared with a loss of $66.8 million a year earlier. Operating margin was -623.6%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $13.00M | $7.00M |
| Growth | +85.71% | — |
| Net income | $-68.87M | $-66.81M |
| EPS (diluted) | $-11.22 | $-45.29 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$21.89+210.94%
- Strong buy 4
- Buy 5
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 10, 2026
- EPS estimate
- $-0.82
- Last reported (Sep/2026)
- Dec 10, 2026
- EPS actual vs est.
- $-0.85 vs $-0.82
- Surprise
- -3.66%
EVMN news
All EVMN newsEvommune peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs EVMN |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs EVMN |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs EVMN |
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs EVMN |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs EVMN |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs EVMN |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs EVMN |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs EVMN |
Indexes, lists and sector
Evommune stock FAQ
What is Evommune's stock price today?
EVMN last traded at $7.04 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.
When is Evommune's next earnings date?
Evommune is expected to report earnings on Thursday, December 10, 2026. Analysts expect EPS of $-0.82.
Who is Evommune's CEO?
Mr. Luis C. Pena is the chief executive officer of Evommune Inc., which has about 48 employees.
What is the EVMN 52-week high?
The 52-week high for EVMN is $33.20 and the 52-week low is $4.94. The stock is currently 78.8% below its high.